Emmaus Life Sciences, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.3M | $2.0M | $3.9M | $3.4M | $2.8M | $2.4M | $3.3M | $5.5M |
| Cost of Revenue | $344.0K | $168.0K | $235.0K | $247.0K | $150.0K | $225.0K | $309.0K | $394.0K |
| Gross Profit | $6.0M | $1.8M | $3.6M | $3.1M | $2.7M | $2.2M | $3.0M | $5.1M |
| Gross Margin | 94.6% | 91.5% | 93.9% | 92.7% | 94.7% | 90.6% | 90.6% | 92.8% |
| Operating Expenses | ||||||||
| Research & Development | $116.0K | $40.0K | $31.0K | $50.0K | $56.0K | $176.0K | $137.0K | $146.0K |
| SG&A Expense | $1.6M | $1.9M | $1.8M | $1.7M | $2.3M | $2.3M | $2.3M | $2.8M |
| Operating Income | $3.8M | $-823.0K | $886.0K | $695.0K | $-370.0K | $-980.0K | $-557.0K | $821.0K |
| Operating Margin | 60.0% | -41.5% | 23.0% | 20.6% | -13.1% | -40.7% | -16.9% | 15.0% |
| Interest Expense | $1.6M | $2.1M | $2.3M | $1.9M | $1.7M | $1.3M | $1.3M | $1.3M |
| Pretax Income | $1.3M | $-3.3M | $-1.9M | $-1.5M | $-1.7M | $-2.3M | $-1.7M | $1.8M |
| Income Tax Expense | $-1.0K | $4.0K | $16.0K | $579.0K | $-590.0K | $4.0K | $6.0K | $-1.0K |
| Net Income | $1.3M | $-3.3M | $-2.0M | $-2.1M | $-1.1M | $-2.3M | $-1.7M | $1.8M |
| Net Margin | 21.2% | -168.3% | -50.6% | -61.5% | -40.3% | -96.8% | -53.1% | 33.4% |
| EPS (Basic) | $0.02 | $-0.05 | $-0.03 | $-0.03 | $-0.02 | $-0.04 | $-0.03 | $0.03 |
| EPS (Diluted) | $0.02 | $-0.05 | $-0.03 | $-0.03 | $-0.02 | $-0.04 | $-0.03 | $0.03 |
| Shares Outstanding (Basic) | 70.2M | 70.2M | 64.0M | 63.9M | 63.9M | 63.9M | 63.2M | 63.9M |
| Shares Outstanding (Diluted) | 120.5M | 70.2M | 64.0M | 63.9M | 63.9M | 63.9M | 63.2M | 63.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |